Clinical Cancer Research  Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schroecksnadel, K.
Right arrow Articles by Fuchs, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schroecksnadel, K.
Right arrow Articles by Fuchs, D.
Clinical Cancer Research Vol. 11, 860, January 2005
© 2005 American Association for Cancer Research


Letter to the Editor

Telomere Length Abnormalities and Human Cancer

Katharina Schroecksnadel, Florian Ueberall and Dietmar Fuchs

Institute of Medical Chemistry and Biochemistry, Innsbruck Medical University, Innsbruck, Austria

With great interest we read the article by Meeker et al. (1) on abnormalities of telomere length occurring early in the initiation of epithelial carcinogenesis. From in situ assessment of telomere length in formalin-fixed human surgical specimens of epithelial cancer precursor lesions, it was concluded that this methodology may be useful as an early biomarker for monitoring disease prevention strategies and for improved early diagnosis.

Telomeres are distinctive structures of a repetitive DNA sequence and associated proteins, which allow cells to distinguish chromosome ends from DNA double-strand breaks. Telomere alterations are observed in senescence and during the immortalization process and may be caused by shortening or direct damage and usually lead to chromosomal instability.

Recent data support the view that immune activation and inflammation and thereby evolving oxidative stress are deeply involved in the development and progression of cancer (2, 3). The tumor microenvironment includes various inflammatory cells, which participate strongly in tumorigenesis and progression of the disease. As Meeker et al. stated, immune activation and inflammation could be involved in telomere shortening. Indeed, telomere shortening was observed in chronic or acute inflammation (e.g., ulcerative colitis, a chronic inflammatory condition predisposing for cancer; ref. 4). An association between telomere abnormalities and immune activation and inflammation is very intriguing to us, because earlier we have found variables of immune activation, such as neopterin, to be sensitive predictors of outcome in several human malignant tumors (5–7). In a similar way, cytokine-inducible expression of indoleamine-2,3-dioxygenase, an enzyme converting tryptophan to kynurenine, was recently observed as an early abnormality in tumorigenesis (8). Likewise, an accelerated tryptophan catabolism predicts shortened survival in patients with cancer (6, 9) and is characteristic for diseases associated with immune activation. For the expression of indoleamine-2,3-dioxygenase and in the increased production of neopterin, pro-inflammatory cytokine IFN-{gamma} is primary (7, 9). IFN-{gamma} is an important mediator of antitumoral defense, which on the one hand enforces forward-regulatory T-cell response mechanisms and on the other hand induces several antiproliferative enzymes in addition to indoleamine-2,3-dioxygenase. IFN-{gamma} also induces high output of cytocidal reactive oxygen species (10). Overall, IFN-{gamma} is probably the most potent growth inhibitor.

At first glance, it is astonishing that shortened survival in cancer patients is associated with higher degree of immune activation and increased formation of IFN-{gamma}. However, it is no surprise that such a potent cytokine has its side effects, and available data imply that IFN-{gamma} released within antitumoral immune response could accelerate the course of malignant process (e.g., by inhibiting T-cell responsiveness; ref. 8). Telomere abnormalities could represent another consequence of chronic immune activation in cancer patients.

REFERENCES

  1. Meeker AK, Hicks JL, Iacobuzio-Donahue CA, et al. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res 2004;10:3317–26.[Abstract/Free Full Text]
  2. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860–7.[CrossRef][Medline]
  3. O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001;85:473–83.[CrossRef][Medline]
  4. O'Sullivan JN, Bronner MP, Brentnall TA, et al. Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat Genet 2002;32:280–4.[CrossRef][Medline]
  5. Prommegger R, Widner B, Murr C, Unger A, Fuchs D, Salzer GM. Neopterin—a prognostic parameter in surgery for lung cancer. Ann Thorac Surg 2000;70:1861–4.[Abstract/Free Full Text]
  6. Huang A, Fuchs D, Widner B, Glover C, Henderson DC, Allen-Mersh TG. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 2002;86:1691–6.[CrossRef][Medline]
  7. Murr C, Fuith LC, Widner B, Wirleitner B, Baier-Bitterlich G, Fuchs D. Increased neopterin concentrations in patients with cancer: indicator of oxidative stress? Anticancer Res 1999;19:1721–8.[Medline]
  8. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9:1269–74.[CrossRef][Medline]
  9. Wirleitner B, Neurauter G, Schröcksnadel K, Frick B, Fuchs D. Interferon-{gamma}-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem 2003;10:1581–91.[CrossRef][Medline]
  10. Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon-{gamma} as the lymphokine that activates human macrophage oxidative metabolism and antimicro0bial activity. J Exp Med 1983;158:670–89.[Abstract/Free Full Text]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schroecksnadel, K.
Right arrow Articles by Fuchs, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schroecksnadel, K.
Right arrow Articles by Fuchs, D.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online